Sequoia Financial Advisors LLC Grows Position in Kenvue Inc. (NYSE:KVUE)

Sequoia Financial Advisors LLC increased its position in Kenvue Inc. (NYSE:KVUE) by 18.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 29,309 shares of the company’s stock after purchasing an additional 4,619 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Kenvue were worth $626,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp raised its stake in Kenvue by 16.8% during the third quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after buying an additional 18,283,473 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Kenvue by 8.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after buying an additional 7,115,374 shares during the last quarter. Holocene Advisors LP raised its stake in Kenvue by 75.5% during the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock valued at $321,194,000 after buying an additional 5,975,392 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Kenvue during the fourth quarter valued at $98,926,000. Finally, FMR LLC raised its stake in Kenvue by 2.3% during the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock valued at $3,189,985,000 after buying an additional 3,075,019 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 2.6 %

KVUE stock opened at $23.41 on Tuesday. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The business’s 50-day moving average is $21.89 and its two-hundred day moving average is $22.40. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market cap of $44.73 billion, a price-to-earnings ratio of 44.16, a P/E/G ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.50%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s payout ratio is 154.72%.

Analysts Set New Price Targets

A number of research analysts have issued reports on KVUE shares. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Piper Sandler upped their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Finally, UBS Group lowered their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $23.75.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.